Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Solid Meal Clear all
Recruiting Phase 1 Interventional

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

NCT07029399
View directory record Official record
Conditions
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions
NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Duarte, California • La Jolla, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Not applicable Interventional

Effects of Wolffia Globosa (Mankai) in Patients Undergoing Bariatric Surgery.

NCT03999632
View directory record Official record
Conditions
Bariatric Surgery Candidate, Diet Modification
Interventions
Dietary modification with introduction of Mankai
Other
Lead sponsor
Cleveland Clinic Florida
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 3, 2026, 3:52 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases

NCT00910039
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sunitinib malate, cognitive assessment
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Not applicable Interventional

Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery

NCT01938469
View directory record Official record
Conditions
Gastric Bypass Surgery, Obesity
Interventions
Liquid Meal, Solid Meal
Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 3, 2026, 3:52 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

The Effects of a High Protein Breakfast on Appetite and Sleep in Young Adults

NCT03031132
View directory record Official record
Conditions
Appetite and General Nutritional Disorders
Interventions
HP-Beverage Breakfast, HP-Solid Breakfast, Breakfast Skipping
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
20 Years to 32 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

NCT05433896
View directory record Official record
Conditions
Pharmacokinetics, Drug Interactions
Interventions
Dasatinib ASD, Omeprazole 40 MG
Drug
Lead sponsor
Xspray Pharma AB
Industry
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

NCT03516487
View directory record Official record
Conditions
Phenylketonuria, Healthy
Interventions
SYNB1618, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Phase 1 Interventional

A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors

NCT02145559
View directory record Official record
Conditions
Breast Neoplasms, Lung Neoplasms, Cancer of Liver, Lymphoma, Cancer of Kidney
Interventions
Metformin XR, Delayed Metformin, Sirolimus
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Phase 2 Interventional Results available

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
View directory record Official record
Conditions
Asthma
Interventions
MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
29
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 3, 2026, 3:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

NCT06598007
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Drug
Lead sponsor
Crossignal Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 3, 2026, 3:52 AM EDT
Terminated No phase listed Observational

Gastric Emptying Using Two Imaging Methods for Those Who Have Undergone POSE2 Weight Loss Procedure

NCT04502732
View directory record Official record
Conditions
Weight Loss
Interventions
NSSM and GEBT
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

NCT04209595
View directory record Official record
Conditions
Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas
Interventions
PLX038, Rucaparib, Ondansetron
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Climate Impact Label Design and Fast-Food Meal Selection

NCT06678178
View directory record Official record
Conditions
Food Selection
Interventions
Control (QR) Labels, Warning High Climate Impact Labels, Traffic Light Labels, Climate Grade Labels, Numeric Carbon Footprint Labels
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
6,622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Phase 4 Interventional Results available

VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK

NCT01205230
View directory record Official record
Conditions
Cancer
Interventions
pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
New Brunswick, New Jersey • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Phase 1 Interventional

GSK1120212 Food-effect Study

NCT01371487
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Detroit, Michigan • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 3, 2026, 3:52 AM EDT
Completed No phase listed Observational

Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders

NCT01137240
View directory record Official record
Conditions
Gastrointestinal Dysfunction, Mitochondrial Disorders
Interventions
gastric emptying scan
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Phase 1 Interventional Results available

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

NCT02783300
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3326595, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Denver, Colorado • Miami, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Phase 1 Interventional

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

NCT03333824
View directory record Official record
Conditions
Solid Tumours
Interventions
CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Sep 3, 2026, 3:52 AM EDT
Completed Phase 1 Interventional

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

NCT01470209
View directory record Official record
Conditions
Solid Tumors, Lung Cancer
Interventions
BKM120, Everolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 3, 2026, 3:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Food Form on Satiety and Gastric Emptying

NCT01102907
View directory record Official record
Conditions
Appetite
Interventions
Liquid Breakfast, Solid Breakfast Meal
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 3, 2026, 3:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

NCT05204862
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
TU2218, Anti-PD-1 antibody
Drug
Lead sponsor
TiumBio Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 3, 2026, 3:52 AM EDT
Not listed Phase 2 Interventional

Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans

NCT02340845
View directory record Official record
Conditions
Cancer
Interventions
Bromelain and Comosain
Biological
Lead sponsor
Oeyama-Moto Cancer Research Foundation
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
West Covina, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Sep 3, 2026, 3:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

NCT06104280
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Post-Illumination Pupillary Response (PIPR), Polysomnography, Multiple Sleep Latency Test, Ecological Momentary Assessments, Actigraphy, DLMO, Melatonin Suppression Test
Other · Behavioral · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 3, 2026, 3:52 AM EDT
Terminated Phase 1 Interventional

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

NCT05300048
View directory record Official record
Conditions
Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation
Interventions
Serabelisib, Insulin Suppressing Diet, Nab paclitaxel
Drug · Other
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Anaheim, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 3, 2026, 3:52 AM EDT